Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

Inhibrx’s INBRX-106 plus Keytruda produced a 44% objective response rate in phase 2 HNSCC, versus 21.4% for Keytruda alone, including three complete responses and none in the control arm. The biotech said the signal is strong enough to advance the HexAgon program, with phase 3 planned for the third quarter and progression-free survival data expected in Q4. The data also reinforce reported Merck interest in the asset and could support a broader oncology pipeline expansion.

Analysis

This read-through is less about a single midphase datapoint and more about whether INBX has converted a long-doubted mechanism into a partnerable platform. If the depth-of-response signal holds, the market will start pricing not just HNSCC optionality but a broader “checkpoint-enhancer” franchise, which is exactly the kind of asset large strategics pay for because it can be slotted into existing PD-1 commercial infrastructure. The key second-order effect is on deal probability: a cleaner efficacy delta materially raises the odds of a takeout before phase 3 de-risks fully, because acquirers prefer to buy the narrative before the asset is broadly valued by public markets.

The competitive impact is more nuanced for MRK than the headline suggests. A successful adjunct to Keytruda does not only defend share in HNSCC; it creates a template to blunt biosimilar erosion by making the standard-of-care bundle harder to displace on efficacy grounds, especially in tumors where physicians already tolerate combination toxicity. That said, if the effect is real, the economic value may accrue disproportionately to whichever company owns the combination standard and trial sequence, so the market may be underestimating how aggressively MRK would need to act to prevent an external partner from monetizing the attach rate.

The biggest risk is timing and phenotype fragility. Early ORR can overstate durability, and the next 1-2 quarters of PFS will determine whether this is a genuine immune-priming effect or simply a response-rate bump with limited survival translation; that matters because the business case for acquisition compresses sharply if the benefit is not durable. There is also a platform-risk overhang: the market has a long memory of OX40 disappointments, so any hint that the signal is confined to highly selected, high-PD-L1, treatment-naïve patients could cap the re-rating and keep the addressable opportunity narrower than bulls assume.

Key Decisions for Investors

• Long INBX on weakness into the PFS readout window; treat this as a binary catalyst trade with upside to M&A valuation, but size for a 3-6 month holding period and a high-volatility tape.
• Buy INBX upside via call spreads rather than outright stock for the next 2-4 months; the setup is asymmetrically positive if takeover chatter intensifies, but clinical disappointment can unwind fast.
• Pair long INBX / short a basket of legacy OX40 overhang names (or use a biotech index hedge) to express the view that hexavalent design, not the target class, is the differentiator.
• For event-driven accounts, consider a tactical long MRK vs short large-cap pharma peers into the possibility of externalization/partnering; if MRK is forced to secure the asset, it may be one of the few near-term pipelines with real strategic urgency.
• Avoid chasing AZN/GSK/PFE on this headline; this is more likely a negative read-through for prior OX40 approaches than a sector-wide immuno-oncology beta trade.